The approval of Xofigo is based on data from the pivotal Phase 3 ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
“Xofigo targets bone metastases, delivering a localized cytotoxic effect to offer patients prolonged survival, making it an exciting advance in the treatment of this cancer.”
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2008, an estimated 899,000 men were diagnosed with prostate cancer and 258,000 died from the disease worldwide. Prostate cancer is the sixth leading cause of death from cancer in men.